Alivus Life Sciences reported robust financial results for Q4 FY26, with standalone net profit climbing 14.66% year-on-year to ₹162.66 crore. According to reports from Business Standard, the company achieved a 6.09% increase in revenue from operations to ₹689.11 crore during the quarter. Profit before tax (PBT) rose 12.81% YoY to ₹215.79 crore, while EBITDA stood at ₹237.3 crore with 13.8% growth compared to ₹208.5 crore in Q4 FY25. The EBITDA margin improved significantly to 34.4% in Q4 FY26 as against 32.1% in Q4 FY25.
The company's revenue performance showed mixed results across segments during Q4 FY26. As reported by Business Standard, revenue from generic API segment rose 6.77% to ₹634.3 crore, while revenue from CDMO segment stood at ₹45.3 crore, up 4.38% from ₹43.4 crore recorded in Q4 FY25. The CDMO business delivered the turnaround planned in the second half, closing the year with 18% YoY growth. The GPL business de-grew by 4.9% during the quarter. Yasir Rawjee, MD & CEO, highlighted that the company witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%.
On a full year basis, Alivus Life Sciences demonstrated strong operational performance with standalone net profit climbing 16.24% to ₹564.48 crore on a 6.91% rise in revenue from operations to ₹2,551.83 crore in FY26 over FY25. According to the company's results, the company generated strong free cash flow of ₹259 crore during FY26, leading to cash and cash equivalents (including short-term investments) of ₹782.4 crore as of March 31, 2026. Tushar Mistry, CFO, noted that for the full year, the company reported EBITDA margins of 33.6%, exceeding the guided range of 30-32%, driven by favourable product mix and disciplined control over operating expenses.
Yasir Rawjee, MD & CEO, stated that the past two years under Nirma's ownership have been a period of transition and evolution that has strengthened the business foundation. As reported by Business Standard, he highlighted that FY26 reflected clear improvement in operating performance with revenue growing 6.9% year-on-year, supported by growth in non-GPL business of 13%. For FY27, the company remains confident of delivering high single-digit revenue growth with margins sustained above 30%, supported by improving operating leverage and rising contribution from new products. The company's board recommended payment of final equity dividend of ₹5 per equity share of face value ₹2 each for FY26.
Tushar Mistry, CFO, noted that for the full year, the company reported EBITDA margins of 33.6%, exceeding the guided range of 30-32%, driven by favourable product mix and disciplined control over operating expenses. According to Business Standard, the company is engaged in the development and manufacturing of select, high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes.
